Targeting IL-17A with ixekizumab was superior to targeting TNF with adalimumab in a head-to-head trial involving 566 biologic DMARD-naive patients with psoriatic arthritis (PsA). All patients enrolled had active skin and joint disease and had previously responded poorly to conventional synthetic DMARDs. At 24 weeks, 36% of patients receiving ixekizumab had reached the primary end point compared with 28% of those receiving adalimumab. Patients receiving ixekizumab also had fewer serious adverse events than those receiving adalimumab.
References
Original article
Mease, P. J. et al. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naÏve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Ann. Rheum. Dis. https://doi.org/10.1136/annrheumdis-2019-215386 (2019)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Collison, J. Ixekizumab superior to adalimumab for PsA. Nat Rev Rheumatol 15, 698 (2019). https://doi.org/10.1038/s41584-019-0326-3
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41584-019-0326-3
